%0 Journal Article
%T 泽布替尼在弥漫大B细胞淋巴瘤临床治疗中的应用研究进展
Research Progress of Application of Zebutinib in the Clinical Treatment of Diffuse Large B-Cell Lymphoma
%A 宋珍
%A 罗伟
%J Journal of Clinical Personalized Medicine
%P 480-485
%@ 2334-3443
%D 2024
%I Hans Publishing
%R 10.12677/jcpm.2024.32070
%X 弥漫大B细胞淋巴瘤(DLBCL)是一种最常见的淋巴增生性疾病,侵袭性强且较难诊断。利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松联合用药(R-CHOP)化学治疗方案是当前DLBCL患者的一线标准治疗方案,但约30%的DLBCL患者采用R-CHOP方案治愈后会复发,预后极差。布鲁顿酪氨酸激酶(BTK)是B细胞受体信号级联中的关键酶,泽布替尼作为不可逆的小分子BTK抑制剂,参与B淋巴细胞的生长、增殖和存活过程,可有效抑制恶性B淋巴细胞的增殖和存活。本文就泽布替尼在DLBCL患者临床治疗中的应用研究进展作一综述。
Diffuse large B-cell lymphoma (DLBCL) is one of the most common lymphoproliferative diseases, which is aggressive and difficult to diagnose. Chemotherapy with rituximab, cyclophosphamide, doxorubicin, chondrine, and prednisone (R-CHOP) is the current first-line standard of treatment for DLBCL patients, but about 30% of DLBCL patients will relapse after being cured with R-CHOP, and the prognosis is very poor. Bruton tyrosine kinase (BTK) is a key enzyme in the B-cell receptor signaling cascade. Zbrutinib, as an irreversible small-molecule BTK inhibitor, participates in the growth, proliferation and survival of B-lymphocytes and can effectively inhibit the proliferation and survival of malignant B-lymphocytes. This article reviews the research progress of the application of zebutinib in the clinical treatment of DLBCL patients.
%K 泽布替尼,弥漫大B细胞淋巴瘤,临床研究
Zerbutinib
%K Diffuse Large B-Cell Lymphoma
%K Clinical Research
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=89481